PDS Biotech Chief Medical Officer, Lauren V. Wood, to Present at the 2021 International Head and Neck Cancer Conference
October 27 2021 - 8:30AM
PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage
immunotherapy company developing novel cancer therapies and
infectious disease vaccines based on the Company’s proprietary
Versamune® T-cell activating technology, today announced that the
company’s Chief Medical Officer, Dr. Lauren V. Wood, will be
presenting at the upcoming 2021 International Head and Neck Cancer
Conference hosted by Cardiff, NHS Wales and The Swallows Head &
Neck Cancer Support Group.
Dr. Lauren V. Wood will be joining Dr. Arthur M.
Lauretano in hosting the 90-minute seminar titled “New Drugs in the
Fight Against Head & Neck Cancer”. This seminar will focus on
novel treatment approaches for head and neck cancer and working in
collaboration with health professionals, patients, cancer survivors
and drug companies in research, prevention, treatment, and care for
those diagnosed with the disease. Dr. Wood will highlight the
potential impact of the Company’s proprietary, Versamune® T-cell
activating technology on the treatment of HPV-associated head and
neck cancer with PDS0101.
The conference is taking place virtually from
November 2 - 4, 2021. Details for the conference and seminar are as
follows:
2021 International Head and Neck Cancer
Conference:Dates: November 2 - 4, 2021Conference Link:
https://www.trybooking.com/uk/events/landing?eid=17014&
Seminar: New Drugs in the Fight Against Head &
Neck CancerDate: Wednesday November 3, 2021Time: 9:15am UK (3:15 am
ET)
Dr. Wood and Dr. Lauretano both bring a breadth of
knowledge and experience to the table. Dr. Wood joined PDS Biotech
as Chief Medical Officer in February 2019. She is responsible for
clinical development of the novel, immune activating Versamune®
platform-based product pipeline that address a broad spectrum of
solid tumors, including PDS Bio’s lead clinical candidate PDS0101
targeting HPV-related cancers. With 30 years of extensive clinical
research experience at the National Institutes of Health, Dr. Wood
most recently was the Clinical Director of the Vaccine Branch,
Center for Cancer Research at the National Cancer Institute. While
there, she oversaw the translational development of immune-based
therapies for both cancer and HIV infection and was a co-inventor
of two patented therapeutic cancer vaccine platforms targeting the
TARP and HER tumor antigens.
Dr. Arthur Lauretano is an otolaryngologist
currently serving as the Medical Director for the Lowell General
Hospital Multidisciplinary Head and Neck Center and as the Chief
Medical Officer at the Circle Health/Lowell General Hospital. Dr.
Lauretano has his Master of Science in Healthcare Management and
Clinical Informatics from the University of Massachusetts Lowell,
and has a second board certification in Clinical Informatics from
the American Board of Preventive Medicine. He is also a fellow of
the American College of Surgeons. Dr. Lauretano also teaches at the
Harvard Medical School and the Boston University School of
Medicine.
About PDS BiotechnologyPDS Biotech
is a clinical-stage immunotherapy company developing a growing
pipeline of cancer immunotherapies based on the Company’s
proprietary Versamune® T-cell activating technology platform. Our
Versamune®-based products have demonstrated the potential to
overcome the limitations of current immunotherapy by inducing in
vivo, large quantities of high-quality, highly potent
polyfunctional tumor specific CD4+ helper and CD8+ killer T-cells.
PDS Biotech has developed multiple therapies, based on combinations
of Versamune® and disease-specific antigens, designed to train the
immune system to better recognize diseased cells and effectively
attack and destroy them. The company’s pipeline products address
various cancers including breast, colon, lung, prostate and ovarian
cancers. To learn more, please visit www.pdsbiotech.com or follow
us on Twitter at @PDSBiotech.
Forward Looking StatementsThis
communication contains forward-looking statements (including within
the meaning of Section 21E of the United States Securities Exchange
Act of 1934, as amended, and Section 27A of the United States
Securities Act of 1933, as amended) concerning PDS Biotechnology
Corporation (the “Company”) and other matters. These statements may
discuss goals, intentions and expectations as to future plans,
trends, events, results of operations or financial condition, or
otherwise, based on current beliefs of the Company’s management, as
well as assumptions made by, and information currently available
to, management. Forward-looking statements generally include
statements that are predictive in nature and depend upon or refer
to future events or conditions, and include words such as “may,”
“will,” “should,” “would,” “expect,” “anticipate,” “plan,”
“likely,” “believe,” “estimate,” “project,” “intend,” “forecast,”
“guidance”, “outlook” and other similar expressions among others.
Forward-looking statements are based on current beliefs and
assumptions that are subject to risks and uncertainties and are not
guarantees of future performance. Actual results could differ
materially from those contained in any forward-looking statement as
a result of various factors, including, without limitation: the
Company’s ability to protect its intellectual property rights; the
Company’s anticipated capital requirements, including the Company’s
anticipated cash runway and the Company’s current expectations
regarding its plans for future equity financings; the Company’s
dependence on additional financing to fund its operations and
complete the development and commercialization of its product
candidates, and the risks that raising such additional capital may
restrict the Company’s operations or require the Company to
relinquish rights to the Company’s technologies or product
candidates; the Company’s limited operating history in the
Company’s current line of business, which makes it difficult to
evaluate the Company’s prospects, the Company’s business plan or
the likelihood of the Company’s successful implementation of such
business plan; the timing for the Company or its partners to
initiate the planned clinical trials for PDS0101, PDS0203 and other
Versamune® based products; the future success of such trials; the
successful implementation of the Company’s research and development
programs and collaborations, including any collaboration studies
concerning PDS0101, PDS0203 and other Versamune® based products and
the Company’s or monitoring committees’ or other third parties’
interpretation of the results and findings of such programs and
collaborations and whether such results are sufficient to support
the future success of the Company’s product candidates; the
success, timing and cost of the Company’s ongoing clinical trials
and anticipated clinical trials for the Company’s current product
candidates, including statements regarding the timing of
initiation, pace of enrollment, significance of milestones, and
completion of the trials (including our ability to fully fund our
disclosed clinical trials, which assumes no material changes to our
currently projected expenses), futility analyses, presentations at
conferences and data reported in an abstract, and receipt of
interim results, which are not necessarily indicative of the final
results of the Company’s ongoing clinical trials; any Company
statements about its understanding of product candidates mechanisms
of action and interpretation of preclinical and early clinical
results from its clinical development programs and any
collaboration studies; the acceptance by the market of the
Company’s product candidates, if approved; the timing of and the
Company’s ability to obtain and maintain U.S. Food and Drug
Administration or other regulatory authority approval of, or other
action with respect to, the Company’s product candidates; and other
factors, including legislative, regulatory, political and economic
developments not within the Company’s control, including unforeseen
circumstances or other disruptions to normal business operations
arising from or related to COVID-19. The foregoing review of
important factors that could cause actual events to differ from
expectations should not be construed as exhaustive and should be
read in conjunction with statements that are included herein and
elsewhere, including the risk factors included in the Company’s
annual and periodic reports filed with the SEC. The forward-looking
statements are made only as of the date of this press release and,
except as required by applicable law, the Company undertakes no
obligation to revise or update any forward-looking statement, or to
make any other forward-looking statements, whether as a result of
new information, future events or otherwise.
Media & Investor Relations
Contact:Deanne RandolphPDS BiotechPhone: +1 (908)
517-3613Email: drandolph@pdsbiotech.com
Rich CockrellCG CapitalPhone: +1 (404)
736-3838Email: pdsb@cg.capital
PDS Biotechnology (NASDAQ:PDSB)
Historical Stock Chart
From Mar 2024 to Apr 2024
PDS Biotechnology (NASDAQ:PDSB)
Historical Stock Chart
From Apr 2023 to Apr 2024